Inspire Medical Stock Price, News & Analysis

Inspire Medical Systems (NYSE: INSP) announced the appointment of Georgia Garinois-Melenikiotou to its Board of Directors, enhancing its leadership with her extensive experience in global consumer marketing and corporate management. Mudit Jain, a founding partner and board member since 2009, will retire at the end of July 2020. CEO Tim Herbert emphasized the importance of diverse expertise for future growth, highlighting Ms. Garinois-Melenikiotou's potential contributions to innovative marketing strategies for Inspire's FDA-approved neurostimulation therapy targeting obstructive sleep apnea.

Inspire Medical Systems, Inc. (NYSE: INSP) plans to release its second quarter 2020 financial results on August 4, following the market close. A conference call will start at 5:00 PM ET to discuss the results and recent business developments. Inspire specializes in innovative, minimally invasive solutions for obstructive sleep apnea, including its FDA-approved neurostimulation technology. For information, visit www.inspiresleep.com.

Inspire Medical Systems (NYSE: INSP) announced that Cigna will provide coverage for its Inspire therapy, effective June 15, 2020. This brings the total coverage to 54 policies, now covering over 180 million members, up from 83 million last year. Additionally, Inspire therapy is set to receive Medicare coverage across the U.S. Cigna's policy deems the FDA-approved device medically necessary for treating moderate to severe obstructive sleep apnea under specific conditions. The company anticipates accelerated growth post-COVID-19 due to these developments.

Inspire Medical Systems (NYSE: INSP) has launched the new Inspire Sleep app, aimed at enhancing patient management for obstructive sleep apnea. This app facilitates telemedicine consultations and follow-up care, meeting the needs of patients and medical practices during challenging times. The app, available on Google Play and the Apple App Store, allows patients to learn about Inspire therapy and connect with trained physicians. Future updates will include clinical data collection and improved patient adherence tracking. Inspire continues to innovate in digital health solutions for better patient outcomes.

Inspire Medical Systems, a leader in medical technology for obstructive sleep apnea, has announced its upcoming presentation at the virtual Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, at 3:50 p.m. Eastern Time. The event will be accessible via a live webcast, which can be found here. A replay will be available for two weeks afterward on Inspire's Investor website. The company offers Inspire therapy, the only FDA-approved neurostimulation technology for effectively treating moderate to severe obstructive sleep apnea.

Inspire Medical Systems (NYSE: INSP) will present at the virtual UBS Global Healthcare Conference on May 20, 2020, at 10:00 a.m. Eastern Time. The live presentation will be accessible through a webcast, with a replay available for two weeks afterward on Inspire’s Investor website. Inspire is a medical technology company specializing in innovative solutions for obstructive sleep apnea, including the first FDA-approved neurostimulation therapy for moderate to severe cases. For more information, visit www.inspiresleep.com.

Inspire Medical Systems (INSP) reported Q1 2020 revenue of $21.3 million, a 31% increase year-over-year. U.S. revenue rose 34% to $19.3 million, while European revenue increased 9% to $2.1 million. The company activated 28 new medical centers, reaching a total of 327, and completed a public offering raising $124.7 million in April. However, the COVID-19 pandemic led to postponements of implant procedures, significantly impacting operations. Inspire withdrew its full-year guidance due to uncertainties surrounding the pandemic.